[{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"COR588","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Lighthouse Pharmaceuticals \/ Cortexyme","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse Pharmaceuticals \/ Cortexyme"},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LHP588","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Lighthouse Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LHP588","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Lighthouse Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Lighthouse Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : LHP588 is the company's next-generation, brain penetrant small-molecule gingipain inhibitor, being developed for the treatment of P. gingivalis-positive Alzheimer's disease.

                          Brand Name : LHP588

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 16, 2023

                          Lead Product(s) : LHP588

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : LHP588 is a Phase 2b, orally available small molecule, targets a specific, infectious pathogen, Porphyromonas gingivalis, associated with chronic degenerative and inflammatory disorders including dementia, periodontal disease, atherosclerosis, and orodig...

                          Brand Name : LHP588

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 10, 2023

                          Lead Product(s) : LHP588

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Under the agreement, Lighthouse gains exclusive rights to develop, manufacture, and commercialize Quince’s legacy protease inhibitor portfolio including, COR588, COR388, COR852, and COR803 globally.

                          Brand Name : COR588

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 30, 2023

                          Lead Product(s) : COR588

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Quince Therapeutics

                          Deal Size : $150.0 million

                          Deal Type : Divestment

                          blank